Protagonist Therapeutics PTGX
NASDAQ PTGX
$134.86 -1.40 (-1.03%)
At close: Nov 11, 2026 · 4:00 PM EST

Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016)

Updated

Protagonist Therapeutics (PTGX) reported Preferred Stock Liabilities of $66.61 million for Q2 2016.

Analysis

Protagonist Therapeutics (PTGX) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends

At the end of FY2015, Protagonist Therapeutics posted Preferred Stock Liabilities of $37 million, up 79.8% from FY2014.

  • By year, Preferred Stock Liabilities came in at $20.58 million in FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Protagonist Therapeutics 8.89 Bn 6.19 Bn 273.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2016 66.61 Mn
Dec 31, 2015 37.00 Mn
API Access

Protagonist Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PTGX&period=max&api_key=YOUR_API_KEY